AbbVie Inc. (ABBV): Price and Financial Metrics
AbbVie Inc. (ABBV)
Today's Latest Price: $107.28 USD
Updated Dec 4 7:00pm
Add ABBV to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ABBV Stock Summary
- ABBV has a higher market value than 99.13% of US stocks; more precisely, its current market capitalization is $185,357,107,176.
- ABBV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.9% of US stocks.
- Over the past twelve months, ABBV has reported earnings growth of 131.89%, putting it ahead of 90.31% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to AbbVie Inc, a group of peers worth examining would be ORCL, CSCO, TMO, ABT, and MRK.
- ABBV's SEC filings can be seen here. And to visit AbbVie Inc's official web site, go to www.abbvie.com.
ABBV Stock Price Chart Interactive Chart >
ABBV Price/Volume Stats
| Current price | $107.28 | 52-week high | $107.31 |
| Prev. close | $104.74 | 52-week low | $62.55 |
| Day low | $105.02 | Volume | 7,235,820 |
| Day high | $107.31 | Avg. volume | 9,669,376 |
| 50-day MA | $92.15 | Dividend yield | 4.4% |
| 200-day MA | $89.99 | Market Cap | 189.40B |
AbbVie Inc. (ABBV) Company Bio
Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.
ABBV Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $107.28 | $340.6 | 224% |
Below please find a table outlining a discounted cash flow forecast for ABBV, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that AbbVie Inc ranked in the 72th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 226%. In terms of the factors that were most noteworthy in this DCF analysis for ABBV, they are:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 68. Notably, its equity weight is greater than just 21.17% of US equities in the Healthcare sector yielding a positive free cash flow.
- AbbVie Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than just 7.91% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 218% |
| 1% | 221% |
| 2% | 224% |
| 3% | 228% |
| 4% | 231% |
| 5% | 234% |
Want more companies with a valuation profile/forecast similar to that of AbbVie Inc? See ALXN, FTLF, ARA, VTRS, and HUM.
Loading social stream, please wait...